Company Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations.
Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2011 |
| IPO Date | May 7, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Jennifer Good |
Contact Details
Address: 195 Church Street, 16th Floor New Haven, Connecticut 06510 United States | |
| Phone | 203 304 2499 |
| Website | trevitherapeutics.com |
Stock Details
| Ticker Symbol | TRVI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001563880 |
| CUSIP Number | 89532M101 |
| ISIN Number | US89532M1018 |
| Employer ID | 45-0834299 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jennifer L. Good | Co-Founder, Chief Executive Officer, President, and Director |
| Dr. James V. Cassella Ph.D. | Chief Development Officer |
| Farrell Simon Pharm.D. | Chief Commercial Officer |
| Dr. Thomas R. Sciascia M.D. | Co-Founder and Chief Scientific Officer |
| David C. Hastings CPA | Chief Financial Officer and Principal Financial Officer |
| Christopher Galletta | Controller and Chief Accounting Officer |
| Katie McManus | Communications Manager |
| Katherine Takaki Ph.D. | Senior Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2026 | ARS | Filing |
| Apr 17, 2026 | 424B5 | Filing |
| Apr 17, 2026 | 8-K | Current Report |
| Apr 16, 2026 | 424B5 | Filing |
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 17, 2026 | 10-K | Annual Report |
| Mar 17, 2026 | 8-K | Current Report |